id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-276641-40r4mitg	Elkhouly, Enas A	Should cancer treatment be continued during the COVID-19 pandemic? A single Egyptian institution experience	2020-07-23		.txt	text/plain	3109	235	60	The aim of this article is based on the fact that the potential threat of COVID-19 to immunocompromised cancer patients as a result of their disease or the treatment delivered is thought to be significant, so it is of great importance to study the best measures to be used by oncology centres to prevent or limit the exposure of cancer patients to COVID-19 and to provide cancer treatment to patients in need, as safely and as correctly as possible. After the appearance of COVID-19 in Egypt, it should be a must to take a rapid action by MCOD, until the arrival of national strategies from higher authorities, so the outpatients were classified into two groups: Group 1 patients under follow-up either as control or hormonal therapy (HT) and Group 2 patients under active treatments (surgery, chemotherapy (ChT), radiotherapy (RT), biological therapy or immunotherapy) either as neoadjuvant or adjuvant treatment or for metastatic disease.	./cache/cord-276641-40r4mitg.txt	./txt/cord-276641-40r4mitg.txt